FDA agrees to review Moderna's flu vaccine after initial rejection

Feb 18, 2026, 2:52 PM10

(Update: Feb 18, 2026, 2:52 PM)

Moderna

American biotechnology company

science

informative

update

FDA agrees to review Moderna's flu vaccine after initial rejection

The FDA initially rejected Moderna's flu vaccine application but later agreed to review it following modifications.
The review includes an application for full approval for adults aged 50-64 and accelerated approval for those aged 65 and older.
Pending FDA approval, Moderna aims to offer the flu vaccine later this year to enhance protection for seniors against influenza.

Moderna

American biotechnology company

Insights

News 1

Reports

Opinions

Story

“

insight insight trends impact market policy policy global geopolitical impact strategic geopolitical data shift economic analysis geopolitical economic insight impact impact policy policy insight market geopolitical policy data trends policy economic policy market strategic insight insight market strategic economic shift data geopolitical shift trends analysis geopolitical impact insight shift strategic trends geopolitical trends trends trends market shift strategic economic trends geopolitical market data market analysis global economic shift geopolitical global economic economic strategic data trends shift analysis market trends market...